Cardiology

Ischemic outcomes don't vary with gender in ACS patients

(HealthDay)—For acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel, prasugrel, or ticagrelor, ischemic outcome does not differ by gender, according to a ...

Cardiology

Vitamin K antagonist plus clopidogrel feasible for PCI

(HealthDay)—Vitamin K antagonists (VKA) combined with clopidogrel may be a better alternative to triple anticoagulant therapy in patients on long-term VKA undergoing percutaneous coronary intervention (PCI) and stenting, ...

Cardiology

Results of the GIANT trial reported

According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes for patients that do not properly metabolize ...

page 1 from 10

Clopidogrel

Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate ADP chemoreceptor. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).

This text uses material from Wikipedia, licensed under CC BY-SA